TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
39.49
+1.50 (3.95%)
Apr 23, 2025, 4:00 PM EDT - Market closed

TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of $5.74 billion. The enterprise value is $5.68 billion.

Market Cap 5.74B
Enterprise Value 5.68B

Important Dates

The next estimated earnings date is Monday, May 5, 2025, before market open.

Earnings Date May 5, 2025
Ex-Dividend Date n/a

Share Statistics

TG Therapeutics has 145.23 million shares outstanding. The number of shares has increased by 7.96% in one year.

Current Share Class 145.23M
Shares Outstanding 145.23M
Shares Change (YoY) +7.96%
Shares Change (QoQ) -0.29%
Owned by Insiders (%) 7.32%
Owned by Institutions (%) 70.66%
Float 134.54M

Valuation Ratios

The trailing PE ratio is 263.27 and the forward PE ratio is 37.97. TG Therapeutics's PEG ratio is 0.34.

PE Ratio 263.27
Forward PE 37.97
PS Ratio 17.44
Forward PS 9.58
PB Ratio 25.57
P/TBV Ratio 25.79
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio 0.34
Financial Ratio History

Enterprise Valuation

EV / Earnings 242.84
EV / Sales 17.26
EV / EBITDA 135.21
EV / EBIT 135.43
EV / FCF n/a

Financial Position

The company has a current ratio of 6.25, with a Debt / Equity ratio of 1.14.

Current Ratio 6.25
Quick Ratio 4.85
Debt / Equity 1.14
Debt / EBITDA 5.74
Debt / FCF n/a
Interest Coverage 1.75

Financial Efficiency

Return on equity (ROE) is 12.21% and return on invested capital (ROIC) is 7.00%.

Return on Equity (ROE) 12.21%
Return on Assets (ROA) 5.78%
Return on Invested Capital (ROIC) 7.00%
Return on Capital Employed (ROCE) 8.61%
Revenue Per Employee $973,385
Profits Per Employee $69,180
Employee Count 338
Asset Turnover 0.73
Inventory Turnover 0.51

Taxes

In the past 12 months, TG Therapeutics has paid $2.21 million in taxes.

Income Tax 2.21M
Effective Tax Rate 8.64%

Stock Price Statistics

The stock price has increased by +180.07% in the last 52 weeks. The beta is 2.14, so TG Therapeutics's price volatility has been higher than the market average.

Beta (5Y) 2.14
52-Week Price Change +180.07%
50-Day Moving Average 36.45
200-Day Moving Average 28.92
Relative Strength Index (RSI) 56.23
Average Volume (20 Days) 2,842,121

Short Selling Information

The latest short interest is 24.89 million, so 17.14% of the outstanding shares have been sold short.

Short Interest 24.89M
Short Previous Month 26.23M
Short % of Shares Out 17.14%
Short % of Float 18.50%
Short Ratio (days to cover) 7.03

Income Statement

In the last 12 months, TG Therapeutics had revenue of $329.00 million and earned $23.38 million in profits. Earnings per share was $0.15.

Revenue 329.00M
Gross Profit 290.52M
Operating Income 41.93M
Pretax Income n/a
Net Income 23.38M
EBITDA 42.00M
EBIT 41.93M
Earnings Per Share (EPS) $0.15
Full Income Statement

Balance Sheet

The company has $311.00 million in cash and $254.38 million in debt, giving a net cash position of $56.62 million or $0.39 per share.

Cash & Cash Equivalents 311.00M
Total Debt 254.38M
Net Cash 56.62M
Net Cash Per Share $0.39
Equity (Book Value) 222.36M
Book Value Per Share 1.54
Working Capital 475.68M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$40.52 million and capital expenditures -$45,000, giving a free cash flow of -$40.56 million.

Operating Cash Flow -40.52M
Capital Expenditures -45,000
Free Cash Flow -40.56M
FCF Per Share -$0.28
Full Cash Flow Statement

Margins

Gross margin is 88.30%, with operating and profit margins of 12.74% and 7.11%.

Gross Margin 88.30%
Operating Margin 12.74%
Pretax Margin 7.78%
Profit Margin 7.11%
EBITDA Margin 12.76%
EBIT Margin 12.74%
FCF Margin n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -7.96%
Shareholder Yield -7.96%
Earnings Yield 0.41%
FCF Yield -0.71%
Dividend Details

Analyst Forecast

The average price target for TG Therapeutics is $40.67, which is 2.99% higher than the current price. The consensus rating is "Strong Buy".

Price Target $40.67
Price Target Difference 2.99%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) 36.90%
EPS Growth Forecast (5Y) 100.29%
Stock Forecasts

Stock Splits

The last stock split was on April 30, 2012. It was a reverse split with a ratio of 0.0177777:1.

Last Split Date Apr 30, 2012
Split Type Reverse
Split Ratio 0.0177777:1

Scores

TG Therapeutics has an Altman Z-Score of 3.11 and a Piotroski F-Score of 3.

Altman Z-Score 3.11
Piotroski F-Score 3